September 19, 2018 | Nora Samaranayake
In partnership with the National Institutes of Health and Amygdala Neurosciences, IHV will test a therapeutic that may prevent craving and relapse for patients with opioid use disorder
The Institute of Human Virology (IHV) at the University of Maryland School of Medicine will lead a $12 million dollar project to improve the morbidity and mortality of people with opioid use disorder (OUD). Utilizing a novel compound, IHV researches will implement a series of investigations, entitled SEARCH, to evaluate the underlying mechanisms of craving reduction as a strategy to prevent opioid misuse, dependence, and relapse. The grant is awarded through the National Institutes of Health’s (NIH) Helping to End Addiction Long-term (HEAL) Initiative, made possible through groundbreaking funding from the U.S. Congress.
“We are pleased to have the opportunity through Dr. Shyam Kottilil’s terrific team here at the Institute to meaningfully address the critical issue of addiction,” said Robert Gallo, MD, The Homer and Martha Gudelsky Distinguished Professor in Medicine, co-founder and director, Institute of Human Virology at the University of Maryland School of Medicine and co-founder and director, Global Virus Network. “Dr. Kottilil and I recently published an op-ed in The Baltimore Sun outlining the importance of better equipping infectious disease specialists to concomitantly treat substance use disorders. This grant is an important step in doing just that.”
“My colleague, Senator Elizabeth Warren and I, introduced legislation this past spring to significantly boost federal funding to combat the rising opioid crisis in the U.S., which leads to tens of thousands of deaths each year,” said U.S. Representative Elijah Cummings (D-Md.). “Baltimore City, one of the hardest hit communities in this national crisis, is a prime location for these clinical trials. I am pleased that the NIH recognizes that the IHV, with its vast expertise, is well-positioned to lead these trials and begin to address the opioid epidemic devastating cities and towns across the nation.”
Nationally, 64,000 Americans died from opioid overdose in 2016, surpassing peak HIV-related deaths at the height of the HIV epidemic. Maryland has one of the fastest rising rates of opioid overdose death in the nation, from 17.7 deaths per 100,000 individuals in 2015, to 30 deaths per 100,000 individuals in 2016. In Baltimore, it is estimated that 11% of Baltimore City residents have a substance use disorder, which underscores the staggering drug overdose death rate of 112.9 deaths per 100,000 individuals in 2016. In 2016, 454 people died as a result of heroin overdose, outpacing the number of homicide-related deaths in the same year.
The investigational agent, ANS-6637, developed by Amygdala Neurosciences, is a selective ALDH2 Inhibitor that may prevent pathophysiologic dopamine surge and associated craving, without changes to basal dopamine. Given the role of craving in the cycle of addiction and relapse, this drug has the potential to be used as pharmacotherapy for any substance and behavior-based addiction.
“We are pleased to partner with the NIH to test this novel therapeutic in our research clinics, with the hope that we can help people living with substance use disorder better manage their disease,” said Shyam Kottilil, MBBS, PhD, professor of medicine, director, Division of Clinical Care & Research, Institute of Human Virology at the University of Maryland School of Medicine.
The six-year project comprises a comprehensive series of investigations led by IHV faculty. The initial investigation, a pre-clinical study of pharmacokinetics, will be conducted at the NIH in collaboration with NIH investigators. Subsequently, the IHV will lead a series of phase II investigations at research sites spanning Washington DC and Baltimore, to evaluate the safety and efficacy of ANS-6637 to reduce craving, drug use, and the risk of comorbid conditions including hepatitis C and HIV.
“While there are evidence-based strategies to reduce harm in individuals with OUD, including medication assisted treatment and syringe exchange, craving remains a major impediment to sobriety,” said Sarah Kattakuzhy, MD, assistant professor of medicine, Institute of Human Virology at the University of Maryland School of Medicine. “The SEARCH investigations will evaluate a new therapeutic mechanism of action, which if successful, could be part of a comprehensive therapeutic strategy that addresses both the physical and psychological symptoms of addiction. The SEARCH program will build upon our research expertise in high throughput phase II investigations, and our experience in hepatitis C treatment and harm reduction in persons with OUD, helping to take clinical care of this marginalized population into the future.”
Learn More:
University of Maryland Virus Institute Joins Hunt for Opioid Treatment
September 19, 2018
By: Meredith Cohn, Contact Reporter
The Baltimore Sun
Robert Gallo: Use HIV Lessons to Stem Opioid Epidemic
August 6, 2018
By: Robert Gallo and Shyam Kottilil
The Baltimore Sun
About the Institute of Human Virology
Formed in 1996 as a partnership between the State of Maryland, the City of Baltimore, the University System of Maryland and the University of Maryland Medical System, IHV is an institute of the University of Maryland School of Medicine and is home to some of the most globally-recognized and world-renowned experts in all of virology. The IHV combines the disciplines of basic research, epidemiology and clinical research in a concerted effort to speed the discovery of diagnostics and therapeutics for a wide variety of chronic and deadly viral and immune disorders - most notably, HIV the virus that causes AIDS. For more information, www.ihv.org and follow us on Twitter @IHVmaryland.
Contact
Institute of Human Virology
Jennifer Gonzales
Public Relations & Communications Manager
jennifer.gonzales@ihv.umaryland.edu
Related stories
Monday, July 17, 2023
Researchers from the Institute of Human Virology Discover that a Bacterial Protein Causes Genomic Instability and Contributes to Reduced Fertility, and Birth Defects
A team of researchers from the University of Maryland School of Maryland’s (UMSOM) Institute of Human Virology (IHV), a Center of Excellence of the Global Virus Network (GVN), published new findings that emphasize the crucial role of the urinary and genital tract microbiota in adverse pregnancy outcomes and genomic instability that originate in the womb during fetal development.
Tuesday, March 28, 2023
Two-Time Lasker Awardee and Internationally Acclaimed Virologist, Robert C. Gallo, MD, To Step Down as Director of UM School of Medicine’s Institute of Human Virology (IHV)
Robert C. Gallo, MD, one of the world’s leading virologists and cancer researchers, announced he has stepped down from his position as Director of the Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM), effective March 24.
Wednesday, November 09, 2022
Lishan Su, PhD, Invested as the UMSOM Charles Gordon Smith Endowed Professor for HIV Research
With his 92-year-old mother watching via live stream from the city of Qingdao, China, and an in-person audience of friends and colleagues gathered in Westminster Hall, Lishan Su, PhD, an internationally prominent virologist and immunologist at the University of Maryland School of Medicine’s (UMSOM) Institute of Human Virology (IHV), was invested as the Charles Gordon Smith Endowed Professor for HIV Research. Dr. Su is a Professor in the Departments of Pharmacology and Microbiology & Immunology at UMSOM’s IHV, who also serves as the Director of the Division of Virology, Pathogenesis, and Cancer at the Institute.
Monday, October 31, 2022
NCI Grants Awarded to IHV to Prevent Cancer and Improve Screening in Sub-Saharan Africa
Institute of Human Virology (IHV) researchers at the University of Maryland School of Medicine (UMSOM) have received two five-year awards from the National Institutes of Health’s National Cancer Institute (NCI) for a total of $7.5 million. One award aims to reduce the incidence of lung cancer and other cancers associated with using tobacco in Botswana. The other is focusing on improving screening and treatment of anal precancer in Nigeria. Both grants will make use of existing HIV treatment and prevention infrastructure in low- and middle-income countries to reach people living with HIV who are most at risk for these particular types of cancers.
Tuesday, February 15, 2022
Multi-Country African Research Reports High Rates of COVID-19-Related Deaths Among Hospitalized Children and Adolescents
African children and adolescents hospitalized with COVID-19 experience much higher mortality rates than Europeans or North Americans of the same age, according to a recently published study conducted by researchers from the Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM) and the Institute of Human Virology Nigeria (IHVN). Both organizations are members of the Global Virus Network (GVN).
Wednesday, December 01, 2021
$6.5M Grant Awarded to Develop Treatment for Alcoholic Liver Disease-Associated Kidney Dysfunction
The Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM) and MitoPower LLC (“MitoPower”) were awarded an SBIR (Small Business Innovation Research) grant of up to $6.5 million over five years from the National Institute on Alcohol Abuse and Alcoholism. The funds will support the development of MitoPower’s lead compound, MP-04, for the treatment of kidney dysfunction due to alcoholic liver disease, a condition known as alcoholic liver disease-associated hepatorenal syndrome (HRS). The IHV, a Center of Excellence member of the Global Virus Network (GVN), will conduct first-in-human single and multiple ascending dose studies to test the safety of the compound, followed by a Phase 1b study in patients.
Tuesday, December 15, 2020
UMSOM Institute of Human Virology’s Shyam Kottilil, MBBS, PhD Receives Top Award from National Physician’s Group
Shyam Kottilil, MBBS, PhD, professor of medicine at the University of Maryland School of Medicine (UMSOM), and Director of UMSOM’s Institute of Human Virology (IHV) Division of Clinical Care and Research, has been awarded Mastership in the American College of Physicians (ACP), the national organization of internists. Dr. Kottilil is also Chief of the Division of Infectious Diseases in the UMSOM Department of Medicine and is a scientific advisory member of the Global Virus Network (GVN).
Thursday, March 21, 2019
IHV Experts Researching Experimental Drug to Curb Opioid Cravings
Researchers at the University of Maryland School of Medicine (UMSOM) Institute of Human Virology (IHV) are collaborating with scientists at the National Institutes of Health to test an experimental drug to curb opioid cravings.
Wednesday, March 06, 2019
UMSOM Researcher Elected as Fellow to American Academy of Microbiology
Richard Y. Zhao, Ph.D., Professor of Pathology and Associate Member of the Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM), has been elected as a Fellow to the American Academy of Microbiology (AAM). AAM is an honorific leadership group within the American Society for Microbiology (ASM).
Tuesday, December 04, 2018
Institute of Human Virology Researchers Discover That a Bacterial Protein Promotes Cancer
The Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM) announced today the discovery that DnaK, a protein of the bacterium mycoplasma, interferes with the mycoplasma-infected cell’s ability to respond to and repair DNA damage, a known origin of cancer.
Wednesday, March 21, 2018
Dr. Robert Redfield, Co-Founder of the Institute of Human Virology at the University of Maryland School of Medicine, to Become CDC Director
The Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM) congratulates its co-founder and associate director, Robert R. Redfield, MD, on his appointment to be the next director of the U.S. Centers for Disease Control and Prevention (CDC).
Tuesday, March 20, 2018
UMSOM Cancer Expert at Institute of Human Virology Named Fellow of American Society of Clinical Oncology
Clement A. Adebamowo, BM, ChB, ScD, FWACS, FACS, Associate Director of Population Science at the Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine (UMSOM), and Professor of Epidemiology and Public Health, Institute of Human Virology, has been named a 2018 Fellow of the American Society of Clinical Oncology (ASCO).
Wednesday, November 29, 2017
To Mark World AIDS Day, Institute of Human Virology Releases Video on Dr. Robert Gallo
The Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM) released a video on Dr. Robert Gallo, a trailblazer in HIV research, in advance of World AIDS Day, December 1. While many know Dr. Gallo for his pioneering work in AIDS research, the short video focuses on Dr. Gallo’s life and legacy in its entirety, including his pioneering discovery of human retroviruses.
Tuesday, November 22, 2016
IHV Awarded $138M to combat HIV/AIDS in Africa & Launches Center for International Health, Education, & Biosecurity
The Institute of Human Virology (IHV) at the University of Maryland School of Medicine announced today more than $138 million in multiple five-year grants awarded by the Centers for Disease Control and Prevention to combat HIV/AIDS in Kenya, Tanzania, Zambia, and Nigeria. The Institute concurrently announced the formation of the IHV Center for International Health, Education, & Biosecurity (CIHEB), and its newly appointed director, Deus Bazira Mubangizi, DrPH, MBA, MPH, Assistant Professor of Medicine, Director, Center for Health, Education, & Biosecurity, Institute of Human Virology, University of Maryland School of Medicine.
Tuesday, October 25, 2016
"A Call to End HIV/AIDS in America" IHV Director Dr. Robert Gallo's Op-Ed in the Huffington Post
As the new Administration is presented with great challenges facing the United States, one will be a longtime foe, the U.S. HIV/AIDS epidemic. Since President Barack Obama was elected in 2008, I have publicly called on our country’s leaders to utilize the largest global health initiative in history - the President’s Emergency Plan for AIDS Relief (PEPFAR) - as a model to address the U.S. epidemic.
Monday, August 22, 2016
Institute of Human Virology (IHV) Awarded $14.4M for HIV Vaccine Research
The Institute of Human Virology (IHV) announced a $14.4M grant from NIAID to advance HIV vaccine research to solve a major challenge: produce long-lasting antibodies to protect against HIV infection.
Wednesday, April 13, 2016
IHV Releases Data Supporting Community-Based Treatment Providers in Fight Against Hepatitis C
The Institute of Human Virology (IHV) at the University of Maryland School of Medicine released data today at The International Liver Congress 2016 in Barcelona, Spain demonstrating that treatment for hepatitis C virus (HCV) can be provided safely and effectively within a community-based and non-specialist setting.
Thursday, March 10, 2016
UM SOM Establishes Two Endowed Professorships Through Private Gifts and Matching State Funds
University of Maryland School of Medicine (UM SOM) Dean E. Albert Reece, MD, PhD, MBA, announced today that the School has been awarded matching funds from the Maryland Department of Business and Economic Development (DBED) as part of the Maryland E-Nnovation Initiative Fund program. The funds, when combined with private philanthropy, will enable UM SOM to establish two new endowed professorships – one in human virology and vaccine development, the other in surgical science and entrepreneurship.